Talazoparib

• Description:

  Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity[1].

• Product Name Alternative:

  BMN-673; LT-673

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  PARP

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/BMN-673.html

• Purity:

  99.89

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  O=C1NN=C2C3=C1C=C(F)C=C3N[C@H](C4=CC=C(F)C=C4)[C@H]2C5=NC=NN5C

• Molecular Formula:

  C19H14F2N6O

• Molecular Weight:

  380.35

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Wang B, et al. Discovery and Characterization of (8S,9R) -5-Fluoro-8- (4-fluorophenyl) -9- (1-methyl-1H-1,2,4-triazol-5-yl) -2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly (ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem. 2016 Jan 14;59 (1) :335-57.|[2]Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.Clin Cancer Res. 2013 Sep 15;19 (18) :5003-15.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  PARP1; PARP2

• Citation 01:

  ACS Appl Mater Interfaces. 2019 Apr 3;11 (13) :12342-12356. |ACS Nano. 2025 May 13;19 (18) :17929-17940. |Adv Sci (Weinh) . 2024 Jul 8:e2400140.|Adv Sci (Weinh) . 2024 May;11 (19) :e2307940.|Am J Cancer Res. 2020 Aug 1;10 (8) :2649-2676.|Am J Cancer Res. 2024 Jan 15;14 (1) :378-389.|Biochem Biophys Res Commun. 2025 Jun 12:776:152203.|Biochem Pharmacol. 2025 May:235:116843.|Bioeng Transl Med. 2019 Jun 14;4 (2) :e10131. |Bioinformatics. 2022 Sep 15;38 (18) :4395-4402.|Biomed Res Int. 2023 Feb 6:2023:7891753.|Biomolecules. 2025 Jul 17;15 (7) :1035.|bioRxiv. 2023 Apr 17.|bioRxiv. 2023 Jun 22:2023.06.22.544406.|bioRxiv. 2023 Jun 28.|bioRxiv. 2024 Jul 10:2024.07.09.602803.|bioRxiv. 2024 Nov 26:2024.11.21.624591.|bioRxiv. 2025 July 08.|bioRxiv. 2025 Nov 4:2025.11.03.686423.|bioRxiv. 2025 Sep 30.|bioRxiv. April 22, 2021.|BMC Cancer. 2022 Mar 23;22 (1) :312.|Br J Cancer. 2024 Jul;131 (2) :231-242.|Cancer Cell Int. 2023 Jun 27;23 (1) :128.|Cancer Cell. 2020 Dec 14;38 (6) :844-856.e7.|Cancer Discov. 2017 Sep;7 (9) :984-998.|Cancer Discov. 2022 Aug 5;12 (8) :1904-1921.|Cancer Lett. 2021 Apr 10:503:197-212.|Cancer Lett. 2021 Mar 1;500:208-219.|Cancer Lett. 2022 Oct 10:546:215851.|Cancer Res. 2021 Jul 1;81 (13) :3480-3494.|Cancer Res. 2023 Nov 15;83 (22) :3813-3826.|Cancer Res. 2025 May 14.|Cell Biosci. 2024 Feb 6;14 (1) :20.|Cell Rep. 2023 Oct 16;42 (10) :113256.|Cell Rep. 2024 Jul 18;43 (8) :114522.|Clin Cancer Res. 2017 Feb 15;23 (4) :1001-1011. |Data Brief. 2021 Sep 22:38:107394.|Département de Pharmacologie et Physiologie, Faculté de Médecine. 2020 Jun.|Drug Des Devel Ther. 2020 Feb 25;14:783-793.|Drug Resist Updat. 2026 Jan:84:101319.|EBioMedicine. 2018 Dec:38:47-56.|EBioMedicine. 2020 Sep;59:102923.|Front Oncol. 2021 Jul 9:11:681441.|Genes (Basel) . 2023 Jun 20;14 (6) :1295.|Int J Cancer. 2024 Jul 15;155 (2) :203-210.|Int J Mol Sci. 2022 Nov 18;23 (22) :14338.|Int J Mol Sci. 2020 Feb 11;21 (4) :1185.|Integr Biol (Camb) . 2019 Apr 1;11 (4) :130-141.|Invest New Drugs. 2021 Oct;39 (5) :1213-1221.|J Clin Invest. 2021 Jun 1;131 (11) :e146256.|J Clin Invest. 2025 Apr 15:e181879.|J Med Chem. 2023 Sep 14;66 (17) :12284-12303.|J Pers Med. 2023 Aug 27;13 (9) :1315.|Methods Mol Biol. 2018:1711:351-398.|Mol Cancer Ther. 2025 Jul 2.|Mol Cell. 2017 May 18;66 (4) :503-516.e5. |Nat Cancer. 2022 Oct;3 (10) :1211-1227.|Nat Commun. 2023 Dec 9;14 (1) :8161.|Nat Commun. 2025 May 12;16 (1) :4239.|Nat Commun. 2019 Jun 11;10 (1) :2556. |Nat Genet. 2022 Dec;54 (12) :1983-1993.|Neoplasia. 2019 Jul 27;21 (9) :863-871.|NPJ Precis Oncol. 2025 Mar 12;9 (1) :69.|NPJ Precis Oncol. 2025 Nov 21;9 (1) :373.|Oncogene. 2017 Aug 17;36 (33) :4682-4691.|Oncogene. 2021 Oct;40 (43) :6143-6152.|Oncogenesis. 2025 Mar 1;14 (1) :4.|Oncol Lett. 2025 Jan 7;29 (3) :128.|Oncol Rep. 2019 Nov;42 (5) :2097-2107.|Oxid Med Cell Longev. 2022 Jul 14:2022:8279269.|Patent. US20180263995A1.|Patent. US20180362972A1.|Patent. US20200078369A1|Patent. US20200129476A1|Patent. US20210030680A1.|Patent. US20220054606A1.|PLoS One. 2024 Apr 16;19 (4) :e0302130.|Proc Natl Acad Sci U S A. 2025 Jun 17;122 (24) :e2426660122.|Radiother Oncol. 2021 Apr:157:175-181.|Research Square Preprint. 2024 Feb 2.|Research Square Print. January 4th, 2023.|Sci Adv. 2022 Feb 18;8 (7) :eabl9794.|Sci Adv. Sci Adv. 2025 Apr 25;11 (17) :eadu0847.|Sci Rep. 2023 Feb 27;13 (1) :3334.|Theranostics. 2020 Jul 25;10 (21) :9477-9494. |University of London. 2021 Sep.|University of Pittsburgh. 2024.|DNA Repair. 2019 Jan:73:64-70.

• CAS Number:

  [1207456-01-6]